Beda Pharmaceuticals

Betta Pharmaceuticals is a leading Chinese biopharmaceutical company primarily focused on the development and commercialization of innovative oncology therapeutics. The company gained significant prominence with the launch of Icotinib (Conmana), the first self-developed small molecule targeted anti-cancer drug in China, which is widely used for EGFR-mutation positive non-small cell lung cancer. Betta maintains a robust pipeline featuring small molecules and biologics targeting various pathways such as ALK, VEGF, and PD-1/PD-L1. Headquartered in Hangzhou, the company operates integrated R&D, manufacturing, and sales platforms to address unmet medical needs in the Chinese and global markets.